Gad Berdugo

Gad Berdugo

  • Managing Partner of Explorium Capital LLC
Print Friendly

Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a New York City based financial and strategic advisory firm focusing on the biotechnology sector, he founded in 2008. He advises private and public companies seeking to fund their activities or seeking to sell or partner their assets via strategic alliances and M&A. He is affiliated with Tripoint Global Equities, a FINRA registered investment bank.

Across his 26+ year career in financial and strategic advisory, investment banking and management and as an international business executive in the biomedical industry, Mr. Berdugo led over $6 billion of financial and strategic advisory mandates, business and corporate development transactions and direct investments into public and private companies. He is experienced at dealing with the full corporate spectrum, from emerging start-ups to multinationals. He brings a unique network of high level relationships within the bio-industry, investment banking and institutional private and public equity investors, on a worldwide basis.

From 2014 to 2015, Mr. Berdugo served as member of the Board of Directors then as EVP, CFO and Corporate Secretary, at Immune Pharmaceuticals Inc., a Nasdaq listed, clinical stage biopharmaceutical company developing targeted monoclonal antibodies and nano-therapeutics against auto-immune diseases and cancer. While at Immune, he helped raise $30 million in growth capital and led several business and corporate development initiatives.

From 2012 to 2014, Mr. Berdugo served as Managing Director and Head of Life Sciences at Tegris Advisors LLC, a New York based advisory boutique where he led several cross border advisory mandates between US based companies and European and Israeli companies, including M&A, reverse mergers and strategic alliances.

In 2009 he launched the Explorium Global Healthcare Fund, providing growth capital to emerging biotech companies via private placements and public offerings. He successffully managed the fund until the end of 2011, returning positive net returns to his Limited Partners, in a very volatile market environement.

From 2001 to 2008, Mr. Berdugo served at Lazard Asset Management Global Equity Group in New York City. Hired as Vice President, Senior Equity Research Analyst and Sector Leader, he was responsible with the team he helped build, for managing $13 billion of investments within the global pharmaceutical, biotech and medical device sectors. He led global investments, including IPOs and M&A situations, based on a proprietary financial valuation framework he developed as well as primary fundamental research. Deeply involved in the capital allocation process, he was credited for making successful investments.

From 1994 to 2001, Mr. Berdugo served at Baxter Healthcare where he had increasing responsibilities in Global Business Development within Baxter’s $2 billion biopharmaceutical group in the corporate headquarters in Illinois and in California. He structured, negotiated and concluded acquisitions and strategic alliances with biotech companies accessing development stage recombinant therapeutic proteins in the fields of immunology, hematology and cancer. Prior to that, he launched Baxter’s Immunotherapy business unit in France. He started his career at Abbott Diagnostics in 1990 in Paris, after working as a biotech research engineer at the Volcani Center (Israel) in collaboration with the Weizmann Institute.

He served on the advisory board of APT Therapeutics, a private biopharmaceutical company; on the advisory board of Spectrum Chemicals, a private life sciences reagents company and on the board of directors of Mabcure, a public, cancer immuno-diagnostics startup. Mr. Berdugo served on the board of directors of the Center of Medicine in the Public Interest, a non-profit organization that seeks to advance personalized medicine. He has been a member of the Faculty of the Tel Aviv University Business School Healthcare Innovation Executive Program since 2008. He is an active member of the Mid Atlantic Bio-Angel Group.

Mr. Berdugo holds both French and US citizenships. He is bilingual in French and English and has conversational skills in Hebrew. Mr. Berdugo received his M.B.A. from H.E.C. School of Management in Paris and studied at Northwestern Kellogg School of Management, his M.Sc. in Biochemical Engineering from University College London and his B.Sc. with Honors in Biotechnology from Imperial College of Science, Technology and Medicine, London.